Contract 75A50324C00006
Elusys Therapeutics Inc · Department Of Health And Human Services · July 23, 2025
Elusys Therapeutics Inc was awarded a federal contract by Department Of Health And Human Services (Office Of Assistant Secretary For Preparedness And Response) on July 23, 2025 for $55.27 million of work in pharmaceutical preparation manufacturing. Performance is in Parsippany, NJ. It was awarded under full and open competition. The contract has been modified 2 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on January 21, 2026. If all options are exercised, the contract could reach $124.52 million.
Contract details
- PIID
- 75A50324C00006
- Award type
- Definitive Contract
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Not Competed
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- Place of performance
- Parsippany, NJ
- First action
- July 23, 2025
- Latest action
- January 21, 2026
Description
ANTHIM (OBILTOXAXIMAB)
Modification timeline
-
January 21, 2026Mod P00005 · Supplemental Agreement For Work Within Scope$124.52M
-
August 22, 2025Mod P00004 · Exercise An Option$124.52M
-
July 23, 2025Mod P00003 · Other Administrative ActionANTHIM - ASSIGNMENT OF CLAIMS$69.25M
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | Department Of Health And Human Services | March 31, 2026 | $122.8K |
| Four Points Technology, L.L.C. | Department Of Health And Human Services | March 31, 2026 | $246.6K |
| Mckesson Corporation | Department Of Health And Human Services | March 30, 2026 | $9.00M |
| Ase Direct, Inc. | Department Of Health And Human Services | March 30, 2026 | $49.0K |
| Emergent Biosolutions Canada Inc | Department Of Health And Human Services | March 30, 2026 | $256.40M |
| Merck Sharp & Dohme Llc | Department Of Health And Human Services | March 27, 2026 | $361.34M |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75A50324C00006?
Contract 75A50324C00006 is a federal contract awarded to Elusys Therapeutics Inc by Department Of Health And Human Services on July 23, 2025 for $55.27 million of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 2 times since the base award.
Who won contract 75A50324C00006?
Elusys Therapeutics Inc won contract 75A50324C00006 from Department Of Health And Human Services.
How much is contract 75A50324C00006 worth?
Contract 75A50324C00006 has obligated $55.27 million to date, with a total potential value of $124.52 million if all options are exercised.